IL187340A - Method of Preparing a Drug Containing 5-Methyl - (s6) - Tetrahydropolyte - Google Patents

Method of Preparing a Drug Containing 5-Methyl - (s6) - Tetrahydropolyte

Info

Publication number
IL187340A
IL187340A IL187340A IL18734007A IL187340A IL 187340 A IL187340 A IL 187340A IL 187340 A IL187340 A IL 187340A IL 18734007 A IL18734007 A IL 18734007A IL 187340 A IL187340 A IL 187340A
Authority
IL
Israel
Prior art keywords
tetrahydrofolate
formulating
medicament
methyl
Prior art date
Application number
IL187340A
Other languages
English (en)
Hebrew (he)
Other versions
IL187340A0 (en
Original Assignee
Merck & Cie
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37396913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL187340(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102005023301A external-priority patent/DE102005023301B4/de
Priority claimed from DE102006016285A external-priority patent/DE102006016285A1/de
Application filed by Merck & Cie, Bayer Ip Gmbh, Bayer Pharma AG filed Critical Merck & Cie
Publication of IL187340A0 publication Critical patent/IL187340A0/en
Publication of IL187340A publication Critical patent/IL187340A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
IL187340A 2005-05-13 2007-11-13 Method of Preparing a Drug Containing 5-Methyl - (s6) - Tetrahydropolyte IL187340A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005023301A DE102005023301B4 (de) 2005-05-13 2005-05-13 Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
DE102006016285A DE102006016285A1 (de) 2006-04-03 2006-04-03 Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
PCT/EP2006/004858 WO2006120035A2 (de) 2005-05-13 2006-05-15 Pharmazeutische zusammensetzung enthaltend gestagene und/oder estrogene und 5-methyl-(6s)-tetrahydrofolat

Publications (2)

Publication Number Publication Date
IL187340A0 IL187340A0 (en) 2011-08-01
IL187340A true IL187340A (en) 2015-03-31

Family

ID=37396913

Family Applications (1)

Application Number Title Priority Date Filing Date
IL187340A IL187340A (en) 2005-05-13 2007-11-13 Method of Preparing a Drug Containing 5-Methyl - (s6) - Tetrahydropolyte

Country Status (37)

Country Link
US (2) US20080160004A1 (enExample)
EP (3) EP2298307A1 (enExample)
JP (2) JP2008540482A (enExample)
KR (2) KR20080028369A (enExample)
CN (2) CN101198332B (enExample)
AR (1) AR054123A1 (enExample)
AT (2) ATE555791T1 (enExample)
AU (1) AU2006245921A1 (enExample)
BR (1) BRPI0611443B8 (enExample)
CA (1) CA2608639C (enExample)
CL (2) CL2009002187A1 (enExample)
CR (1) CR9531A (enExample)
CY (2) CY1109261T1 (enExample)
DE (1) DE502006003617D1 (enExample)
DK (2) DK2116249T3 (enExample)
DO (1) DOP2006000110A (enExample)
EA (2) EA028530B1 (enExample)
EC (1) ECSP078001A (enExample)
ES (2) ES2325600T3 (enExample)
GT (1) GT200600200A (enExample)
HR (1) HRP20090418T1 (enExample)
IL (1) IL187340A (enExample)
MA (1) MA29448B1 (enExample)
MY (1) MY147362A (enExample)
NO (1) NO345807B1 (enExample)
PE (1) PE20061415A1 (enExample)
PL (2) PL1888077T3 (enExample)
PT (2) PT2116249E (enExample)
RS (2) RS52651B (enExample)
SG (1) SG169973A1 (enExample)
SI (2) SI2116249T1 (enExample)
SV (1) SV2008002527A (enExample)
TN (1) TNSN07418A1 (enExample)
TW (1) TWI380820B (enExample)
UY (1) UY29527A1 (enExample)
WO (1) WO2006120035A2 (enExample)
ZA (2) ZA200710811B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
MX2009000256A (es) * 2006-07-06 2009-02-18 Bayer Schering Pharma Ag Preparaciones farmaceuticas para la anticoncepcion y para prevenir el riesgo de malformaciones congenitas.
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
EP1891959A1 (de) * 2006-08-14 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
BRPI0810049A2 (pt) * 2007-04-05 2015-05-05 Bayer Schering Pharma Ag Regime de drospirenona/17beta-estradiol, produto de combinação farmacêutica e kit para realizar esse regime
EA201070715A1 (ru) * 2007-12-20 2011-02-28 Тева Вимен'С Хелс, Инк. Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции
WO2009112232A2 (en) * 2008-03-10 2009-09-17 Vladimir Hanes New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
WO2009112231A2 (en) * 2008-03-10 2009-09-17 Schuermann Rolf New drospirenone/17beta-estradil regimen, pharmaceutical combination product and kit for performing this regimen
BR112012026115B1 (pt) 2010-04-15 2019-12-24 Bayer Ip Gmbh forma de dosagem oral sólida, seu uso, e unidade de acondicionamento
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP2617422A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate
EP2781214A1 (en) * 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
CN107812195B (zh) * 2014-09-04 2021-04-20 连云港金康和信药业有限公司 (6s)‐5‐甲基‐四氢叶酸钙盐的稳定药物组合物
JP6863547B2 (ja) 2015-06-18 2021-04-21 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
JP6866560B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CN106336444A (zh) * 2016-08-23 2017-01-18 国家卫生计生委科学技术研究所 一种新晶型炔雌醇
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK174724B1 (da) * 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
ZA939565B (en) * 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.
US6083528A (en) * 1995-09-28 2000-07-04 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
JPH11513989A (ja) * 1995-10-27 1999-11-30 メルク エンド カンパニー インコーポレーテッド 成長ホルモン分泌促進薬の湿式造粒製剤
US5997915A (en) 1996-01-31 1999-12-07 South Alabama Medical Science Foundation Compositions for human and animal consumption containing reduced folates and methods for making and using same
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
UA68365C2 (en) * 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
CN1240387C (zh) * 1998-04-17 2006-02-08 奥索一麦克尼尔药品公司 含有叶酸的药用组合物及其用途和给药系统
EP1121139A1 (en) * 1998-10-19 2001-08-08 MERCK PATENT GmbH Natural formulation for the treatment and prevention of depression, containing st john's wort and derivatives of dihydro- and tetrahydrofolic acid
US7014865B1 (en) 1998-10-19 2006-03-21 Merck Patent Gmbh Natural formulation for the treatment and prevention of depression, containing St. John's Wort and derivatives of dihydro- and tetrahydrofolic acid
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
HU225779B1 (en) 1999-07-28 2007-08-28 Chinoin Gyogyszer Es Vegyeszet Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
RS50262B2 (sr) 1999-08-31 2018-10-31 Bayer Pharma AG Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US6479545B1 (en) 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
DE10022510A1 (de) 2000-05-10 2001-11-15 Basf Ag Zusammensetzungen enthaltend Folsäure und reduziertes Folat
US20020094970A1 (en) * 2000-12-14 2002-07-18 Ronenn Roubenoff Compositions and methods for treating an arthritic condition
US20030045510A1 (en) * 2000-12-15 2003-03-06 Schloss Caroline Maxine Estrogen-plus
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
US20060034954A1 (en) * 2001-02-02 2006-02-16 Bland Jeffrey S Medical composition for balancing bodily processes
US20040220118A1 (en) * 2001-02-02 2004-11-04 Bland Jeffrey S. Medical composition for balancing bodily processes
RS50909B (sr) * 2002-02-21 2010-08-31 Bayer Schering Pharma Aktiengesellschaft Farmaceutske kompozicije koje se sastoje od jednog ili više steroida, jedne ili više tetrahidrofolatne komponente i vitamina b12
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.

Also Published As

Publication number Publication date
BRPI0611443A2 (pt) 2010-09-08
EA028530B1 (ru) 2017-11-30
SV2008002527A (es) 2008-03-27
ES2387525T5 (es) 2024-07-05
JP5883810B2 (ja) 2016-03-15
ES2325600T3 (es) 2009-09-09
ZA200908894B (en) 2025-01-29
BRPI0611443B8 (pt) 2021-05-25
EA200901393A1 (ru) 2010-02-26
DK1888077T3 (da) 2009-08-17
KR20080028369A (ko) 2008-03-31
JP2008540482A (ja) 2008-11-20
MA29448B1 (fr) 2008-05-02
TNSN07418A1 (en) 2009-03-17
ATE429917T1 (de) 2009-05-15
NO345807B1 (no) 2021-08-16
DK2116249T3 (da) 2012-08-20
EP2116249B1 (de) 2012-05-02
TWI380820B (zh) 2013-01-01
CA2608639A1 (en) 2006-11-16
PE20061415A1 (es) 2007-01-26
EA014664B1 (ru) 2010-12-30
GT200600200A (es) 2007-03-23
CL2009002187A1 (es) 2010-10-01
ZA200710811B (en) 2012-06-27
CR9531A (es) 2008-02-21
AU2006245921A1 (en) 2006-11-16
EP1888077B1 (de) 2009-04-29
KR101598735B1 (ko) 2016-03-02
CN101198332B (zh) 2012-07-18
HK1118729A1 (en) 2009-02-20
IL187340A0 (en) 2011-08-01
RS50972B (sr) 2010-10-31
SI1888077T1 (sl) 2009-10-31
AR054123A1 (es) 2007-06-06
CA2608639C (en) 2013-04-30
DE502006003617D1 (de) 2009-06-10
EP2298307A1 (de) 2011-03-23
WO2006120035A3 (de) 2007-02-15
PT2116249E (pt) 2012-08-07
NO20076408L (no) 2008-02-12
EP1888077A2 (de) 2008-02-20
PL1888077T3 (pl) 2009-12-31
ECSP078001A (es) 2008-01-23
ES2387525T3 (es) 2012-09-25
JP2013166753A (ja) 2013-08-29
TW200711651A (en) 2007-04-01
BRPI0611443B1 (pt) 2020-07-21
US20080160004A1 (en) 2008-07-03
EP2116249B2 (de) 2023-04-05
ATE555791T1 (de) 2012-05-15
HRP20090418T1 (hr) 2009-09-30
KR20140069175A (ko) 2014-06-09
SI2116249T1 (sl) 2013-02-28
EA200702349A1 (ru) 2008-04-28
CL2010000989A1 (es) 2011-02-18
CY1114403T1 (el) 2016-08-31
SG169973A1 (en) 2011-04-29
DOP2006000110A (es) 2012-06-15
CY1109261T1 (el) 2014-07-02
UY29527A1 (es) 2006-12-29
PT1888077E (pt) 2009-07-20
US20160095860A1 (en) 2016-04-07
PL2116249T3 (pl) 2013-06-28
EP2116249A1 (de) 2009-11-11
CN101198332A (zh) 2008-06-11
CN101954083A (zh) 2011-01-26
US10463666B2 (en) 2019-11-05
WO2006120035A2 (de) 2006-11-16
RS52651B (sr) 2013-06-28
MY147362A (en) 2012-11-30

Similar Documents

Publication Publication Date Title
IL187340A (en) Method of Preparing a Drug Containing 5-Methyl - (s6) - Tetrahydropolyte
ZA200810605B (en) Substituted pyrazolopyrimidines,a process for their preparation and their use as medicine
PL1877017T3 (pl) Wyrób chłonny typu majtek
ZA200802272B (en) Novel dosage formulation
ZA200903840B (en) Powder formulation for valganciclovir
IL213720A0 (en) Tiotropium salts
IL182739A0 (en) Acylatednonadepsipeptides used as lysobactin derivatives
PL1942967T3 (pl) Sposób dozowania leków
GB0500643D0 (en) Medicaments
AP2007004282A0 (en) Derivatives of A 1-phenyltriazole as antiparasiticagents
GB0713798D0 (en) Process for the preparation of a boron-substituted porphyrin
EP1938808A4 (en) PREPARATION FOR TOPICAL APPLICATION
SI2054416T1 (sl) Substituirani pirazolopirimidini, postopek za njihovo pripravo in njihova uporaba kot zdravilo
GB0402491D0 (en) Medicaments
GB0403733D0 (en) Medicaments
EP1853258A4 (en) DRUGS
PL1688129T3 (pl) Nowy preparat terapeutyczny
GB2431120B (en) Revolution counter for wrist exerciser
GB2406659B (en) Medical clock
PL1641438T3 (pl) Sposób wytwarzania amorficznej postaci leku
GB0409098D0 (en) Medicament
GB0426942D0 (en) Medicament
GB0610570D0 (en) Novel formulation
GB0417979D0 (en) A disinfection formulation
ZAF200500429S (en) A medicament holder

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed